Editorial: Phosphodiesterases as Drug Targets in Airway and Inflammatory Diseases.
作者信息
Mokry Juraj, Giembycz Mark, Mokra Daniela
机构信息
Department of Pharmacology, Jessenius Faculty of Medicine, Comenius University, Martin, Slovakia.
Department of Physiology and Pharmacology, University of Calgary, Calgary, AB, Canada.
出版信息
Front Pharmacol. 2021 Apr 12;12:657596. doi: 10.3389/fphar.2021.657596. eCollection 2021.
Abstract
摘要
相似文献
1
Editorial: Phosphodiesterases as Drug Targets in Airway and Inflammatory Diseases.社论：磷酸二酯酶作为气道和炎症性疾病的药物靶点
Front Pharmacol. 2021 Apr 12;12:657596. doi: 10.3389/fphar.2021.657596. eCollection 2021.
2
Roflumilast: a selective phosphodiesterase 4 inhibitor.罗氟司特：一种选择性磷酸二酯酶4抑制剂。
Drugs Today (Barc). 2005 Oct;41(10):667-75. doi: 10.1358/dot.2005.41.10.920428.
3
Phosphodiestrase-1 and 4 inhibitors ameliorate liver fibrosis in rats: Modulation of cAMP/CREB/TLR4 inflammatory and fibrogenic pathways.磷酸二酯酶-1 和 4 抑制剂改善大鼠肝纤维化：cAMP/CREB/TLR4 炎症和纤维化途径的调节。
Life Sci. 2019 Apr 1;222:245-254. doi: 10.1016/j.lfs.2019.03.014. Epub 2019 Mar 8.
4
A Novel, Pan-PDE Inhibitor Exerts Anti-Fibrotic Effects in Human Lung Fibroblasts via Inhibition of TGF-β Signaling and Activation of cAMP/PKA Signaling.一种新型的泛 PDE 抑制剂通过抑制 TGF-β 信号和激活 cAMP/PKA 信号通路在人肺成纤维细胞中发挥抗纤维化作用。
Int J Mol Sci. 2020 Jun 3;21(11):4008. doi: 10.3390/ijms21114008.
5
[Selective phosphodiesterase-4 (PDE-4) inhibitors in COPD].[慢性阻塞性肺疾病中的选择性磷酸二酯酶-4（PDE-4）抑制剂]
Tuberk Toraks. 2008;56(4):472-84.
6
Dose dependent effects of tadalafil and roflumilast on ovalbumin-induced airway hyperresponsiveness in guinea pigs.他达拉非和罗氟司特对卵清蛋白诱导的豚鼠气道高反应性的剂量依赖性影响。
Exp Lung Res. 2017 Nov-Dec;43(9-10):407-416. doi: 10.1080/01902148.2017.1386735. Epub 2017 Dec 8.
7
8
Phosphodiesterases as therapeutic targets for respiratory diseases.磷酸二酯酶作为治疗呼吸疾病的靶点。
Pharmacol Ther. 2019 May;197:225-242. doi: 10.1016/j.pharmthera.2019.02.002. Epub 2019 Feb 10.
9
The phosphodiesterase-4 inhibitor roflumilast impacts Schistosoma mansoni ovipositing in vitro but displays only modest antischistosomal activity in vivo.磷酸二酯酶-4 抑制剂罗氟司特可影响曼氏血吸虫体外产卵，但在体内仅显示出适度的抗血吸虫活性。
Exp Parasitol. 2020 Jan;208:107793. doi: 10.1016/j.exppara.2019.107793. Epub 2019 Nov 8.
10
Effect of Roflumilast in airways disorders via dual inhibition of phosphodiesterase and Ca-channel.罗氟司特通过双重抑制磷酸二酯酶和钙通道对气道疾病的作用。
Saudi Pharm J. 2020 Jun;28(6):698-702. doi: 10.1016/j.jsps.2020.04.011. Epub 2020 Apr 25.
引用本文的文献
1
Efficacy and safety of ensifentrine in treatment of COPD: a systematic review and meta-analysis of clinical trials.恩昔芬净治疗慢性阻塞性肺疾病的疗效与安全性：一项临床试验的系统评价和荟萃分析
Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251347775. doi: 10.1177/17534666251347775. Epub 2025 Jun 20.
2
Phosphodiesterase Inhibitors in Acute Lung Injury: What Are the Perspectives?磷酸二酯酶抑制剂在急性肺损伤中的应用：前景如何？
Int J Mol Sci. 2021 Feb 16;22(4):1929. doi: 10.3390/ijms22041929.
本文引用的文献
1
Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD.依诺司林（RPL554）：一种用于治疗 COPD 的研究性 PDE3/4 抑制剂。
Expert Opin Investig Drugs. 2019 Oct;28(10):827-833. doi: 10.1080/13543784.2019.1661990. Epub 2019 Sep 1.
2
The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a]isoquinolin-4-one].两种新型长效磷酸二酯酶3/4抑制剂RPL554 [9,10-二甲氧基-2(2,4,6-三甲基苯基亚氨基)-3-(N-氨基甲酰基-2-氨基乙基)-3,4,6,7-四氢-2H-嘧啶并[6,1-a]异喹啉-4-酮]和RPL565 [6,7-二氢-2-(2,6-二异丙基苯氧基)-9,10-二甲氧基-4H-嘧啶并[6,1-a]异喹啉-4-酮]的药理学。
J Pharmacol Exp Ther. 2006 Aug;318(2):840-8. doi: 10.1124/jpet.105.099192. Epub 2006 May 8.
Zotero 插件